Labiotech.eu

News and Trends 6 Jul 2016

June was a Tough Month for European Biotech… #Fail

Abivax, Celyad, Circassia and Genticel – these are all European Biotechs that took a hit after failing key clinical trials in June. How are they doing now? Four different public Biotechs suffered setbacks in some of their advanced clinical trials. And, as always, the words ‘failed to meet primary endpoint‘ weren’t very popular with investors… […]

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

biogeneration capital ventures finance money fund biotech medtech

News and Trends 5 Jul 2016

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

BioGeneration Ventures has had its first close of a new venture capital fund, ‘BioGeneration Capital Fund III’, for novel diagnostic, medtech and therapeutic biotechs in Europe. BioGeneration Ventures (BGV) is based in Naarden (Netherlands) and manages funds investing in Netherlands, Belgium and Germany. Some of its biotech porfolio companies have included Dezima Pharma (acquired by Amgen from […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

deskgen desktop genetics biotech labiotech refresh crispr

News and Trends 5 Jul 2016

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

The problem with CRISPR, is that not many people are actually experts in the field, and there are only a select few who worked on it pre-2013. So how did this UK Startup make a big name for itself in field of the ‘Biotech Breakthrough of the Century’? Desktop Genetics is a startup founded in 2012 by three […]

July 5, 2016 - 4 minutesmins - By Dani Bancroft

cinfa amgen biosimilar biotech neutropenia chemotherapy

News and Trends 5 Jul 2016

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

The Spanish Cinfa Biotech’s race to compete with Amgen’s blockbuster for Chemotherapy-induced Neutropenia continues: the Neulasta biosimilar passes Phase I trials. Neulasta (pegfilgrastim) is a slightly longer acting version of Amgen’s other blockbuster Neupogen (the template for the first ever US approved biosimilar – from Novartis), the combined sales of which account for over 30% of Amgen’s income. […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

leo pharma astrazeneca dermatology biologics

News and Trends 4 Jul 2016

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Leo Pharma is acquiring rights to two of AstraZeneca‘s candidates. The targeted indications are atopic dermatitis and psoriasis – autoimmune conditions getting more and more attention. Based near Copenhagen (Denmark), Leo Pharma specializes in dermatological therapies – particularly topical treatments. The company is not shy about its acquisitions, having entered a €675M deal to buy Japanese […]

July 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

morphosys thrombosis phaseI novartis hucal

News and Trends 4 Jul 2016

Novartis delivers German Biotech’s 12th Antibody to Clinics

MorphoSys keeps up its impressive productivity in feeding pipelines. Its 12th antibody in its Novartis collaboration has just reached clinical development. After presenting results for two of its wholly-owned candidates at ASCO 2016 (you can get an insider look into ASCO from the team), MorphoSys is receiving good news on the collaborations’ front. One of the […]

July 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

uk biohackathon cambridge cutec 2016 biohacking alpha brick

News and Trends 4 Jul 2016

What kind of Startups were born at the UK’s First Biohackathon?

Organised by the University of Cambridge Technology and Enterprise Club (a catchy ‘CUTEC’ for short), the Biohackathon was the first of its kind organised in the UK… With SynBio veterans such as Bento Bio (inventors of the ‘Lunch box sized Laboratory’ for hackers, schools and DIY enthusiasts), Synthace (which invented Antha – ‘the programming language of […]

July 4, 2016 - 5 minutesmins - By Dani Bancroft

abivax ceo ehrlich interview hiv hepatitis

News and Trends 4 Jul 2016

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Abivax has recently announced that it’s likely that its most advanced program in hepatitis B will fail its Phase III trials. That’s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company’s CEO Hartmut […]

July 4, 2016 - 5 minutesmins - By Denise Neves Gameiro

kathy high bioart biomedical research blood rats

News and Trends 2 Jul 2016

Blood Wars and Celebrating the Unsung Rats of Science with #BioArt

Kathy High is an American artist exploring the areas of technology, science, speculative fiction and art. She does this with installations and workshops – including one where the audience’s blood fights each other. Kathy High studied fine arts, English literature, video and photography at New York. On top of having a lot of well-known work in […]

July 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Jul 2016

37% of all Living Nobel Laureates urged Greenpeace to stop anti-GMO campaigns

The GMO debate is back into mainstream news, as 110 Nobel laureates (out of the 297 living) signed a ‘cease and desist’ open letter to Greenpeace. The target is its anti-GMO campaign, which they deem anti-scientific. And Golden Rice is the spearhead of the accusations… How many poor people in the world must die before […]

July 1, 2016 - 5 minutesmins - By Denise Neves Gameiro

bristol myers squibb immunooncology cancer opdivo psioxus

News and Trends 1 Jul 2016

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients. Together they will evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Opdivo blockbuster (nivolumab), which […]

July 1, 2016 - 3 minutesmins - By Dani Bancroft

biotech discuva cambridge drug discovery brexit header

News and Trends 1 Jul 2016

Drug-resistant Bacteria should fear Discuva’s antimicrobials

Duty calls on the Island of Queen Elizabeth II…. What will be the future of Biotech in the United Kingdom and in Europe? Last week we did a review to catch up with all the details of #Brexit and this is why we decided to head up to Cambridge, one of the major biotech and research centers in the […]

July 1, 2016 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

June was a Tough Month for European Biotech… #Fail

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Novartis delivers German Biotech’s 12th Antibody to Clinics

What kind of Startups were born at the UK’s First Biohackathon?

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Blood Wars and Celebrating the Unsung Rats of Science with #BioArt

37% of all Living Nobel Laureates urged Greenpeace to stop anti-GMO campaigns

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Drug-resistant Bacteria should fear Discuva’s antimicrobials

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!